Healthcare Stocks
Below are all our articles under the above category.
The Long Goodbye: Why Australian Active Fund Managers Are Running Out of Road
Australian Active Fund Managers are struggling, make no mistake. Hitting home the point yesterday were reports that Ox Capital Management…
Here are 5 ASX Stocks That Should Be Merged or Be Acquired, and Why the Logic Is Compelling
Despite the dour state of the markets right now, it could be time for certain ASX stocks that should be…
Sigma Healthcare rerating rests on delivering $100m merger synergies
Sigma Healthcare (ASX: SIG) now turns on one fact above all others: the Chemist Warehouse merger has transformed a low-growth…
Here Are 6 Questions Investors Need To Ask About Their Portfolio To Get The Best Possible Returns!
There are hard questions investors need to ask about their portfolio every now and again, because anyone telling you there’s…
The 4 Best ASX Healthcare Stocks to Buy as the Sector Trades at Two-Decade Valuation Lows
4 ASX Healthcare Stocks to Buy at Valuation Lows ASX healthcare stocks have had a brutal run. Five years of…
Lumos Diagnostics (ASX: LDX) Falls Despite FDA Win- Here’s Why the Dip Could Be a Buying Opportunity
Lumos Diagnostics Falls After FDA Waiver Lumos Diagnostics (ASX: LDX) slipped around 3.8% on Friday despite announcing one of the…
The Mayo Clinic will use 4DX’s CT:VQ and investors are thrilled
Another day, another piece of good news from 4DX Medical (ASX:4DX), today news the Mayo Clinic would be employing the…
The Impact of The Iran War Extends Beyond Oil, And this ASX Company is the Poster Child for It!
It is easy to think the Impact of The Iran War is simply businesses in the oil space or that…
Is Echo IQ (ASX:EIQ) a Buy? Mayo Clinic Deal and ASX Index Entry Signal a Major Turning Point
Echo IQ Gains on Mayo Deal and FDA Filing Echo IQ (ASX: EIQ) surged 17% on Tuesday on the back…
Rhythm Biosciences’ ColoSTAT has been commercialised and the roll out will ramp up fast!
Rhythm Biosciences‘ colorectal cancer test ColoSTAT is officially on the market and has made its first sale. In our view,…
T-Cell Lymphoma is a very deadly cancer, but this ASX stock has a treatment in a Phase 2 trial!
Prescient Therapeutics‘ (ASX:PTX) trial of PTX-100 against T-Cell Lymphoma is well and truly underway now with 8 out of…
Same Theme, Better Choices: Here Are 5 ASX Stocks Not To Buy, And 5 To Buy Instead!
It is easy to think of ASX Stocks that are a compelling case to buy, but tougher to think of…
Tetratherix (ASX: TTX) Surges 22% After Signing US$30 Million GLP-1 Deal: Is TTX a Buy Right Now?
Tetratherix jumps on new US GLP-1 deal Tetratherix (ASX: TTX) surged 22% on Monday after signing an exclusive deal with…
Telix (ASX:TLX) Pixclara NDA Resubmitted, The FDA Clock Restarts
Pixclara Back With the FDA Telix has resubmitted its NDA to the FDA for Pixclala, its PET imaging agent for…
Here are 5 ASX Biotech Targets Amidst The $230bn Patent Cliff; And Which Big Pharma Companies Could Buy Them!
There are plenty of ASX Biotech Targets that major pharmaceutical companies wanting to minimise the impact of the Patent Cliff…
Immutep’s Phase 3 trial for Efti has gotten the chop and shares plunge >90%! What now for investors?
After nearly a week in suspense, Immutep (ASX:IMM) confirmed news about Efti that its investors did not want to hear,…
Orthocell (ASX: OCC) Lines Up UK Distributor for Remplir Ahead of Approval- Is Now the Time to Buy?
Orthocell Moves Closer to UK Growth Orthocell (ASX: OCC) just made a move that not every small-cap medtech company would…
What does the 2026 health insurance premium rise mean for ASX health insurance stocks?
The 2026 health insurance premium rise is in, and it is 4.41%. It made headlines because it is ahead of…
Pro Medicus (ASX: PME) Falls Despite A$40m in US Renewals: Is This a Buying Opportunity?
Pro Medicus Dips Despite Strong Renewals Pro Medicus (ASX: PME) slipped around 1% on Monday despite announcing approximately A$40m in…
Nanosonics (ASX:NAN) Revenue Up 9%, But Operating Leverage Still Missing
Nanosonics Investors Want Margin Accretion, This Half Did Not Deliver It Nanosonics saw its share price fall 7% to around…
Here are 4 ASX biotechs with major milestones coming right up!
Investing in ASX biotechs is a risky business, even more than most other companies on the market. Unless you own…
Is Fisher & Paykel Healthcare (ASX:FPH) a Buy After Upgrading Guidance? The Tariff Risk Investors Are Ignoring
Fisher & Paykel Healthcare (ASX: FPH) lifted its FY26 guidance on Monday, now expecting around NZ$2.30 billion in revenue and…
Telix (ASX:TLX) Could Be A Turnaround Story (Investing for FY26)
Illuccix Still Prints, Gozellix Adds a New Growth Leg Telix saw a small rerate this morning after releasing its full…
Alcidion (ASX:ALC) Wins Dual AI Healthcare Approval After Swinging to Profit- Time to Buy or Wait?
Alcidion Clears a Key AI Approval Hurdle Alcidion Group (ASX: ALC) hit a regulatory milestone that could open up its…
If you wondered why share prices fall after a capital raising, Botanix is the ‘perfect’ poster child
We thought this was a perfect time to ponder the question,’ Why share prices fall after a capital raising’, in…
Botanix (ASX:BOT) Down 40% on a $45m Raise, Dilution Shock Hits Hard
A Steep Discount, A Big Dilution, A New Valuation Anchor Botanix started the session with a sharp sell off, falling…
Rhythm Biosciences (ASX:RHY): Since picking up Genetype, it has never looked back and is more than a one-trick pony!
Investors may remember Rhythm Biosciences (ASX:RHY) for its ColoSTAT test, but it is Genetype that is arguably more exciting. The…
Ansell (ASX:ANN) Proves It Can Pass On Trump’s Tariffs – But With Shares Down 13%, Is It a Buy?
Ansell Shrugs Off Tariffs with Strong Pricing Power Ansell (ASX: ANN) reported half-year results on Monday that told a story…
Australian Clinical Labs (ASX:ACL) The Statutory Hit Spooked Investors
Australian Clinical Labs fell 10% today after revenue went slightly backwards, even though underlying profit improved. The key nuance is…
Why ASX Healthcare Stocks Are Crashing- and Which One Looks Like a Buy
ASX healthcare stocks are crashing- which one is worth buying now? Three of Australia’s most premium ASX healthcare stocks have…
Cochlear (ASX:COH) Down 16% on a Softer Half, What the Market Is Really Pricing
Cochlear had a softer start to its half yearly result, with sales of A$1.1 billion down around 1%. The bigger…
Pro Medicus (ASX:PME) Down 16% on a Great Result, Here’s Why
A Premium Multiple Leaves No Room for “Good” Pro Medicus fell 16% despite what, on the surface, looked like an…
A Blood Test Instead of a Colonoscopy? Rhythm Biosciences (ASX:RHY) Takes Its First Commercial Step
Rhythm Biosciences Starts ColoSTAT Pilot, Revenue Still Unclear Rhythm Biosciences (ASX: RHY) just hit a milestone the market has been…
CSL CEO Paul McKenzie has departed, now what for the fallen biotech giant?
In a bombshell 4pm announcement, investors learned that CSL CEO Paul McKenzie was departing the company effective that very afternoon…
This company just made an IND submission to the US FDA, here’s why its a big step!
Imagion Biosystems (ASX:IBX) just made a IND submission. This is a big deal for the company, and we thought it…
Immutep (ASX: IMM) Hits Key Phase III Milestone: Buy the Dip or Take Profits Before the Critical Data Readout?
Immutep (ASX: IMM) has pulled back roughly 22 per cent from its recent 52-week high near A$0.46, settling around A$0.36…
The 50% CGT discount on shares: Here’s how it works, and if it is under threat
The 50% CGT discount on shares is one of the key mechanisms that helps investors keep as much of their…
PYC Therapeutics (ASX:PYC): Its been raising ~$650m to fund 4 clinical assets for multiple years!
PYC Therapeutics (ASX:PYC) is currently in the Top 25 ASX healthcare stocks and is the 4th largest biotech, only trailing…
Island Pharmaceuticals (ASX:ILA) Raises A$9M as FDA Confirms Galidesivir Pathway: Is This Small-Cap Biotech a Buy?
Island Pharmaceuticals jumps after FDA backs galidesivir pathway Island Pharmaceuticals (ASX: ILA) surged as much as 23% to an intraday…
Neuren (ASX:NEU) Crashes 10% on EU Setback: Is This a Buying Opportunity?
Neuren Pharmaceuticals: Is the 10% drop a buy signal? Neuren Pharmaceuticals (ASX: NEU) dropped nearly 10% on Tuesday, falling to…
Is it Time to Buy ResMed (ASX:RMD)? It is Crushing the Ozempic Fear Narrative with New Data!
ResMed data shows GLP-1 users use CPAP more Is it time to buy ResMed (ASX: RMD)? Well, the company is…
Is Telix Pharmaceuticals (ASX:TLX) a Buy After Crashing 63%? Here’s What Investors Should Know
Telix Pharmaceuticals Shares Slide After Regulatory Setbacks Telix Pharmaceuticals (ASX: TLX) has had a brutal twelve months. Shares have fallen…
What happened to Botanix (ASX:BOT) and why are investors sweating
From A$0.53 to A$0.118 Botanix Shows How Fast Biotech Narratives Turn Botanix (ASX:BOT) is a clear example of how quickly…
Compumedics (ASX:CMP): Expecting $70m sales but trading at barely over 1x Revenues, is this a buy?
Some investors may think Compumedics (ASX:CMP) is highly undervalued. It trades at $75m, a level that many clinical-stage medtech or…
Aroa Biosurgery (ASX: ARX): Why This Newly Profitable Medtech Looks Like a Buy at Current Levels
Aroa Biosurgery adds new trauma study as profits turn positive Aroa Biosurgery (ASX: ARX) shares have seen increased activity this…
Fisher and Paykel (ASX:FPH): It exports sleep apnea products to 120 countries, but here’s why ResMed is a better buy
If there was one ASX company brutally honest about the fact that it could not escape an impact from Trump’s…
Anteris Technologies (ASX: AVR) Surges 30% on Medtronic Deal- Is It a Buy?
Anteris Technologies Gains Momentum with Medtronic Partnership Anteris Technologies (ASX: AVR) jumped more than 30% after announcing a deal that…
Epiminder (ASX:EPI): Less than 2 months since its IPO, this medtech made its first implant
Epiminder (ASX:EPI) only listed on the ASX at the end of November last year, but just announced to market that…
Osteopore (ASX:OSX) Secures A$2.6M China Deal: Micro-Cap Opportunity or Too Risky to Buy?
Osteopore signs a major China distribution deal, but risks remain Osteopore (ASX: OSX) surged 71 per cent last Friday after…
Proteomics International (ASX:PIQ) Appoints New CEO as US Sales Push Begins: Is It Time to Buy?
Proteomics International begins its US sales push as Medicare reimbursement starts At Proteomics International (ASX: PIQ), new CEO David Morris takes…
Zelira Therapeutics (ASX:ZLD) A 170% Surge Backed by Smart, Non-Dilutive Funding
External Validation Sends Shares Flying Zelira Therapeutics shares surged as much as 172% intraday, before settling around 73.5 cents, following…
5 ASX Healthcare Companies with Game Changing Milestones in 2026!
2026 is set to be a big year for several ASX Healthcare Companies, especially companies in the pre-commercialisation stage. The…
Singular Health (ASX:SHG) Gains FDA Clearance for Cloud Imaging Platform: Is This MedTech a Buy Now?
Singular Health secures FDA clearance for US rollout Singular Health Group (ASX: SHG) grabbed investor attention on Tuesday after the…
Telix Pharmaceuticals (ASX:TLX) Through the Commercialisation Chasm
The Market Lost Patience, the Strategy Did Not Telix Pharmaceuticals (ASX:TLX) is one of the more compelling examples of a…
EBR Systems (ASX:EBR) Surges 7.6% on Q4 Momentum: Time to Buy Before Full US Launch?
EBR Systems Gains Momentum Ahead of 2026 US Launch EBR Systems (ASX: EBR) is building serious momentum as it moves…
Imricor Medical (ASX:IMR) FDA Approval Ignites Shares, but the Real Test Starts Now
FDA Approval Is a Big Win, Not the Finish Line Imricor Medical (ASX:IMR) received FDA clearance for its Vision-MR diagnostic…
Mesoblast (ASX:MSB) Delivers 60% Jump in Ryoncil Sales, Strengthening Commercial Momentum
Mesoblast Lifts on Ryoncil Growth Mesoblast (ASX:MSB) delivered a very strong performance this morning following a positive guidance update for…
Cochlear (ASX:COH) is still a long term growth story you should listen to
Cochlear is one of few stocks that has created immense shareholder value and has also greatly improved the lives of…
Ansell (ASX:ANN) Drops 6% on CEO Exit: Is This a Buying Opportunity?
Is Ansell’s CEO Change a Hidden Opportunity for Investors? Ansell (ASX: ANN) fell over 6% on Thursday after announcing that…
Novo Nordisk (CPH: NOVO-B): It’s not all smooth sailing for the US$180bn company behind obesity drug Ozempic
Not many 100-year old healthcare stocks see a sudden 30% jump in sales in one year and become the largest…
Sonic Healthcare (ASX:SHL): Australia’s biggest pathology stock is available at a bargain price
It is not often that you can buy a blue-chip stock at a bargain price, but Sonic Healthcare (ASX:SHL) is…
Ozempic and other GLP-1 Drugs: Here’s Where Things Are Headed in 2026
At Stocks Down Under, it has been a while since we’ve looked at Ozempic and other GLP-1 Drugs. Investors paid…
Stocks Down Under’s Top 10 Hottest ASX Stocks to Look At in 2026!
Today, on the first trading day of 2026, Stocks Down Under publishes its its 10 Hottest ASX Stocks to Look…
Monash IVF (ASX:MVF) Plunges 15% as $312m Takeover Bid Collapses- Is This a Buying Opportunity?
Monash IVF: Is This a Buying Opportunity? Monash IVF (ASX: MVF) shares crashed 15% to 69.5 cents last week after…
Our 5 ASX Predictions for 2026!
This article outlines 5 ASX Predictions for 2026 that Stocks Down Under puts its neck on the line to assert…
Invion (ASX:IVX) Surges 20% on Non-Dilutive Funding for Cancer Program
Invion Secures Non-Dilutive Backing to Advance Cancer Therapy Invion (ASX:IVX) saw a sharp rerating today, with the share price rising…
Is Pro Medicus (ASX:PME) a Buy After the 34% Pullback?
Pro Medicus slips, growth momentum remains Pro Medicus (ASX: PME) has dropped approximately 34% from its record high of A$336…
Regis Healthcare (ASX:REG) Drops Below $7.20 on CEO Exit: A Buying Opportunity?
Regis Healthcare CEO Exit: What Investors Watch Next Regis Healthcare (ASX: REG) shares fell 2.6% to A$7.13 after CEO Dr…
Is Telix Pharmaceuticals (ASX:TLX) Now Undervalued With Phase 3 China Clinical Success?
Why Telix Pharmaceuticals Pullback Could Be a Second Chance Telix Pharmaceuticals (ASX:TLX) has faced a challenging year, particularly for a…
Telix Pharmaceuticals (ASX:TLX) Down 55% Amid Lawsuit: Is It Time to Buy or Sell?
Telix Pharmaceuticals (ASX: TLX) has been crushed in 2025. The stock has fallen roughly 55% from its February high of…
Neuren Pharmaceuticals (ASX:NEU) Gets FDA Approval- Is It a Buy?
Neuren Pharmaceuticals (ASX: NEU) rose 2.5% yesterday after the US FDA approved DAYBUE STIX, a new powder formulation of its…
Medibank Private shares have recovered the losses after the cyber breach 2 years ago, but what’s next?
Medibank Private shares took a big hit nearly 3 years ago due to the infamous cyber breach. Investors who chose…
Is Rhythm Biosciences (ASX:RHY) a Buy After Securing NHS Expertise and US Distribution Deal?
Rhythm Biosciences (ASX: RHY) may finally be turning the corner. The company has secured NHS expertise to support its ColoSTAT…
Orthocell (ASX:OCC) Surges 7% on First Hong Kong Sales: Is This Healthcare Stock a Buy as Asian Expansion Accelerates?
Orthocell (ASX: OCC) jumped 7% to A$1.09 on Wednesday after announcing its first commercial sales of Remplir in Hong Kong.…
4DMedical’s Growth Story Gains Airflow in the US Market
4DMedical Finds Its Rhythm 4DMedical (ASX:4DX) climbed 9% today as the company continues to build strong commercial momentum with its…
Cogstate (ASX:CGS) Sells Off 22% on Timing Delay, But the Fundamentals Stay Intact
Cogstate’s H1 Hit Is a Timing Story, Not a Demand Story Cogstate Ltd (ASX:CGS) delivered a business update this morning…
Immutep (ASX:IMM) Surges on US$369M Global Partnership With Dr. Reddy’s
Immutep Lands Global Deal With Dr. Reddy’s Immutep (ASX:IMM) surged 23% at market open after announcing a new strategic partnership…
Here are 6 stocks that got promoted in the ASX quarterly rebalance, and 6 that got demoted
On Monday December 22, the ASX quarterly rebalance will be effective. Stocks will be promoted into new indices, while others…
Telix Pharmaceuticals (ASX:TLX) Back on Track, First Patient Dosed in Phase 3 PROSTACT Trial
TLX Delivers Clinical Progress It’s good to finally see some positive news from Telix Pharmaceuticals (ASX:TLX) after a relatively quiet…
Mayne Pharma (ASX: MYX) Threatens to Terminate A$672M Cosette Deal- Is the Stock a Buy at A$3.39?
The tables have turned, and shareholders face a key decision as the 10 December deadline approaches. Mayne Pharma (ASX: MYX)…
Saluda Medical (ASX:SLD) IPO Raises $230M, but Crashes 46% on its Trading Debut
Saluda Medical (ASX:SLD) listed on Friday after raising AU$230 million at AU$2.65 per share, marking a rare bright spot in…
Optiscan Imaging (ASX: OIL) Launches Second Cancer Trial: Why This MedTech Stock Looks Like a Buy
Optiscan Imaging (ASX: OIL) has partnered with Australian Clinical Labs to launch Australia’s first-in-human head and neck cancer imaging study.…
Epiminder (ASX: EPI) Makes ASX Debut After Raising $125M for FDA-Approved Epilepsy Device
Epiminder (ASX: EPI) made its ASX debut on Monday after raising $125 million at $1.50 per share, giving the company…
Paragon Care Acquires Haju Medical for $70M as Asia Aesthetics Push Accelerates
Paragon Care (ASX: PGC) is betting big on Asia. The healthcare distributor, currently trading near its 52-week lows around $0.29,…
This Phase 2 ASX Biotech stock is only at cash backing, but has enormous upside!
Phase 2 Biotech stocks on ASX tend to be capitalised at $40-110m, but Percheron Therapeutics (ASX:PER) is only at cash…
Zeotech (ASX:ZEO): Stronger and low-carbon concrete derived from Queensland kaolin!
Zeotech (ASX:ZEO) is attempting to play a part in helping reduce emissions from the construction sector. Over the last few…
Pro Medicus Surges 3% on $29M US Contracts: Buy the Dip or Sell Into Strength at 200x Earnings?
Pro Medicus (ASX: PME) jumped 3% this morning to $258.50 after announcing $29 million in new US contracts spanning three…
Monash IVF Soars 40% After Rejecting $0.80 Takeover: Buy on Momentum or Sell Before Deal Collapses?
Monash IVF (ASX: MVF) surged 40% today to $0.855 after the company’s board unanimously rejected an $0.80-per-share takeover proposal from…
Johnson and Johnson (NYSE:JNJ): Firmly on the Big Pharma M&A bandwagon
Johnson and Johnson (NYSE:JNJ) is arguably one of the big pharma companies least at risk from the Patent cliff. It…
Mayne Pharma Surges on Takeover Panel Ruling: Buy for the 24% Upside or Too Risky?
Mayne Pharma (ASX: MYX) jumped 24% to $5.96 after the Takeovers Panel gave a ruling that may save its $672…
Sonic Healthcare Reports Strong FY25: Is This Healthcare Giant a Buy After Earnings?
Sonic Healthcare (ASX: SHL) recently reaffirmed its FY26 earnings guidance at its annual general meeting, confirming the company remains on…
Thermo Fisher (NYSE:TMO): A classic blue-chip health stock for the rest of the 2020s
Capped at over US$180bn, Thermo Fisher (NYSE:TMO) is a classic blue-chip healthcare stock. It has not escaped an impact from…
Prescient Therapeutics (ASX:PTX): It has taken the plunge into a Phase 2 trial against T-Cell Lymphoma
There’s plenty of ASX oncology biotechs conducting clinical trials, but Prescient Therapeutics (ASX:PTX) is one of the closest to commercialisation.…
Is Pro Medicus Still a Buy at 150x Earnings? What the Valuation Means for Investors
Pro Medicus (ASX: PME) trades at a valuation that defies conventional wisdom. Despite a 25% pullback from July’s $336 peak…
Island Pharmaceuticals Soars 32% After FDA Clears Galidesivir for Animal Rule Pathway
Island Pharmaceuticals Surges 32 Percent on Transformational FDA Decision for Galidesivir Island Pharmaceuticals (ASX: ILA) jumped 32% this morning after…
Zoono Slips 40% as Multisteps Deal Delivers Smaller Near Term Orders
Early Mpact Orders Come In Light, Testing Short-Term Expectations Zoono (ASX: ZNO) is a stock we have been tracking closely…
Vectus Biosystems Shares Rocket 60% After IP Deal with XORTX Therapeutics
Vectus Biosystems Hits Inflection Point: 60% Share Spike When Licensing Kidney-Fibrosis Drug to XORTX Therapeutics Vectus Biosystems (ASX: VBS) surged…
Avita Medical (ASX:AVH): It hasn’t catapulted it to the heights envisioned (yet), but there’s hope for the 2026 and 2027
Avita Medical (ASX:AVH/NDQ:RCEL) is a particularly peculiar healthcare stock. The company, these days based in the Californian city of Valencia…
ResMed (ASX:RMD) Plunges 4% Despite Solid Q1: What’s Wrong?
ResMed (ASX: RMD) dropped nearly 5% on Monday despite reporting solid quarterly results. The sleep apnea treatment company delivered revenue…
Imricor Medical Systems Shares Jump 12% After World-First MRI-Guided Heart Procedure
Imricor Jumps 12% After World-First MRI-Guided Heart Procedure Validates Clinical Potential Imricor Medical Systems (ASX: IMR) jumped 12 percent today…